Latest Genta Incorporated Stories
Genta Incorporated (OTCBB: GNTA) announced the presentation of a progress update from the Company's ongoing Phase 3 trial of Genasense(R) (oblimersen sodium) Injection, Genta's lead oncology product, in patients with advanced melanoma.
BERKELEY HEIGHTS, N.J., July 14 /PRNewswire-FirstCall/ -- Genta Incorporated (BULLETIN BOARD: GNTA) announced that the Food and Drug Administration (FDA) has accepted the Company's amendment to its New Drug Application (NDA) for Genasense(R) (oblimersen sodium) Injection as a "complete response".
- A woman chauffeur.
- A woman who operates an automobile.